title: A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria.
abstract: OBJECTIVE
  To compare the renoprotective effects of the calcium channel blocker (CCB) benidipine (CAS 105979-17-7) and the angiotensin II receptor blocker (ARB) valsartan (CAS 137862-53-4) in primary hypertensive patients with proteinuria.
  
  
  METHODS
  236 patients with primary hypertension were randomly divided into different groups and were administered either benidipine or valsartan. The alterations of the glomerular filtration rate (GFR) and proteinuria were compared between the different groups.
  
  
  RESULTS
  Valsartan could decrease the level of proteinuria significantly as compared with that in benidipine-treated hypertensive patients with proteinuria at levels <1 g/24 h (P < 0.01). There was no significant difference of the effects of benidipine and valsartan on proteinuria reduction in hypertensive patients with proteinuria at levels 1-3 g/24 h. There was no significant difference of the effects of benidipine and valsartan on GFR in benidipine- and valsartan-treated patients.
  
  
  CONCLUSIONS
  The results showed that valsartan was more effective in decreasing the levels of proteinuria in hypertensive patients with proteinuria at an early stage of nephropathy. The renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria were similar.
authors.affiliation: Department of Nephrology, Shandong University Qilu Hospital, Jinan, P. R. China.
authors.forename: Tao
authors.initials: T
authors.lastname: Peng
authors.forename: Zhao
authors.initials: Z
authors.lastname: Hu
authors.forename: Qing
authors.initials: Q
authors.lastname: Xia
authors.forename: Bei
authors.initials: B
authors.lastname: Jiang
authors.forename: Xianhua
authors.initials: X
authors.lastname: Li
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Yang
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000150:complications*; D012079:Renal Circulation / Q000187:drug effects*; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D013777:Tetrazoles; C061004:benidipine; D000068756:Valsartan; D014633:Valine